Tofacitinib for the Treatment of Steroid-Induced Rosacea
Tianhao Li, Henghong Wang, Caiying Wang, Pingsheng Hao
Abstract
Purpose: Conventional treatment suffers from a dilemma of poor efficacy. The clinical use of Janus kinase (JAK) inhibitors in the treatment of steroid-induced rosacea has rarely been explored. Patients and Methods: We present a case of steroid-induced rosacea successfully treated with JAK inhibitor tofacitinib, with no adverse effects. Results: This case report of successful treatment shows a good clinical efficacy of JAK inhibitors tofacitinib in the treatment of SIR. Conclusion: JAK inhibitor tofacitinib may be a promising agent for the treatment with steroid-induced rosacea, especially for patients who have failed to conventional therapy.
Topics & Concepts
TofacitinibRosaceaMedicineJanus kinaseDermatologyAdverse effectTopical steroidSteroidJanus kinase inhibitorPharmacologyInternal medicineReceptorAcneRheumatoid arthritisHormoneAcne and Rosacea Treatments and EffectsPharmacological Effects of Natural CompoundsHerpesvirus Infections and Treatments